Juniper Pharmaceuticals (JNP) 10-Q 2 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	JNP
Entity Registrant Name	JUNIPER PHARMACEUTICALS INC
Entity Central Index Key	821,995
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		10,844,113

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 22,106	$ 20,994
Accounts receivable, net	6,521	6,573
Inventories	5,897	5,621
Prepaid expenses and other current assets	2,152	1,539
Total current assets	36,676	34,727
Property and equipment, net	15,127	13,366
Intangible assets, net	817	969
Goodwill	9,056	8,342
Other assets	79	167
Total assets	61,755	57,571
Liabilities, contingently redeemable preferred stock, and stockholders’ equity
Accounts payable	4,607	3,893
Accrued expenses and other	5,739	5,271
Deferred revenue	7,444	5,624
Current portion of long-term debt	535	204
Total current liabilities	18,325	14,992
Long-term debt, net of current portion	3,369	2,203
Other noncurrent liabilities	148	56
Total liabilities	21,842	17,251
Commitments and contingencies
Contingently redeemable series C preferred stock, 0 and 0.55 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively (liquidation preference of $550)		550
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,000 shares authorized Series B convertible preferred stock, 0 and 0.13 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively (liquidation preference of $0 and $13 as of September 30, 2017 and December 31, 2016, respectively)
Common stock $0.01 par value; 150,000 shares authorized; 12,257 issued and 10,844 outstanding at September 30, 2017 and December 31, 2016	123	123
Additional paid-in capital	291,857	290,636
Treasury stock (at cost), 1,413 shares at September 30, 2017 and December 31, 2016	(8,601)	(8,601)
Accumulated deficit	(240,128)	(237,360)
Accumulated other comprehensive loss	(3,338)	(5,028)
Total stockholders’ equity	39,913	39,770
Total liabilities, contingently redeemable preferred stock, and stockholders’ equity	$ 61,755	$ 57,571

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,257,000	12,257,000
Common stock, shares outstanding	10,844,000	10,844,000
Purchase of treasury shares	1,413,000	1,413,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	0	550
Preferred stock, shares outstanding	0	550
Preferred stock, liquidation preference, value	$ 550	$ 550
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	130
Preferred stock, shares outstanding	0	130
Preferred stock, liquidation preference, value	$ 0	$ 13

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues
Product revenues	$ 8,389,000	$ 7,057,000	$ 25,684,000	$ 20,716,000
Service revenues	4,597,000	3,337,000	12,505,000	9,964,000
Royalties		1,162,000		2,963,000
Total revenues	12,986,000	11,556,000	38,189,000	33,643,000
Cost of product revenues	5,160,000	3,683,000	14,776,000	11,892,000
Cost of service revenues	2,559,000	2,022,000	7,149,000	6,630,000
Total cost of revenues	7,719,000	5,705,000	21,925,000	18,522,000
Gross profit	5,267,000	5,851,000	16,264,000	15,121,000
Operating expenses
Sales and marketing	517,000	259,000	1,306,000	910,000
Research and development	2,291,000	2,304,000	5,285,000	8,234,000
General and administrative	3,238,000	3,111,000	12,263,000	9,815,000
Restructuring charge	756,000		756,000
Total operating expenses	6,802,000	5,674,000	19,610,000	18,959,000
(Loss) income from operations	(1,535,000)	177,000	(3,346,000)	(3,838,000)
Interest expense, net	(47,000)	(24,000)	(105,000)	(74,000)
Other income, net	127,000	90,000	179,000	296,000
Total non-operating income	80,000	66,000	74,000	222,000
(Loss) income before income taxes	(1,455,000)	243,000	(3,272,000)	(3,616,000)
Income tax (benefit) expense	(45,000)	(5,000)	(45,000)	47,000
Net (loss) income	$ (1,410,000)	$ 248,000	$ (3,227,000)	$ (3,663,000)
Basic net (loss) income per common share	$ (0.13)	$ 0.02	$ (0.26)	$ (0.34)
Diluted net (loss) income per common share	$ (0.13)	$ 0.02	$ (0.26)	$ (0.34)
Basic weighted average common shares outstanding	10,844	10,799	10,817	10,791
Diluted weighted average common shares outstanding	10,844	11,060	10,817	10,791

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (1,410)	$ 248	$ (3,227)	$ (3,663)
Other comprehensive income (loss) components:
Foreign currency translation	639	(658)	1,690	(2,863)
Total other comprehensive income (loss)	639	(658)	1,690	(2,863)
Comprehensive income (loss)	$ (771)	$ (410)	$ (1,537)	$ (6,526)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net income (loss)	$ (3,227)	$ (3,663)
Reconciliation of net loss to net cash provided by operating activities:
Depreciation and amortization	1,668	1,435
Stock-based compensation expense	1,216	804
Changes in operating assets and liabilities:
Accounts receivable	356	1,680
Inventories	(274)	(1,215)
Prepaid expenses and other current assets	(550)	282
Other non-current assets	88	18
Accounts payable	897	2,836
Accrued expenses and other	298	354
Deferred revenue	1,761	1,149
Net cash provided by operating activities	2,233	3,680
Investing activities:
Purchases of property and equipment	(2,404)	(2,256)
Net cash used in investing activities	(2,404)	(2,256)
Financing activities:
Proceeds from loan facility	954
Proceeds from equipment loans	1,501
Principal payments on debt	(1,269)	(175)
Dividends paid	(14)	(21)
Net cash provided by (used in) financing activities	1,172	(196)
Effect of exchange rate changes on cash and cash equivalents	111	(158)
Net increase in cash and cash equivalents	1,112	1,070
Cash and cash equivalents, beginning of period	20,994	13,901
Cash and cash equivalents, end of period	22,106	14,971
Supplemental cash flow information
Cash paid for interest	85	$ 67
Supplemental noncash information
Purchases of equipment through accounts payable and accrued expenses	100
Series C Preferred Stock [Member]
Supplemental noncash information
Excess of carrying value of Series C Preferred Stock over redemption value	$ 459

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Interim Condensed Consolidated Financial Statements	(1) Interim Condensed Consolidated Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) for the year ended December 31, 2016 filed with the SEC on March 7, 2017 (the “2016 Annual Report”). In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of September 30, 2017, and its results of operations for the three and nine months ended September 30, 2017 and 2016, and cash flows for the nine months ended September 30, 2017 and 2016. The condensed consolidated balance sheet at December 31, 2016, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements. Results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results for the year ending December 31, 2017 or any period thereafter. At September 30, 2017, cash and cash equivalents were $22.1 million. The Company’s future funding requirements depend on a number of factors, including the rate of market acceptance of its current and future products and services and the resources the Company devotes to developing and supporting the same. The Company believes that current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet anticipated cash needs for working capital, including potentially advancing a product candidate, and capital expenditures through the next twelve months from the date of the filing of this Form 10-Q. The Company may be dependent on its ability to raise additional capital to finance operations and further fund research and development programs. If the Company is not able to raise additional capital on terms acceptable to it, or at all, as and when needed, it may be required to curtail its operating spend including spend related to its research and development programs. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, restructuring charges and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): September 30, 2017 December 31, 2016 Raw materials $ 2,020 $ 856 Work in process 3,099 3,806 Finished goods 778 959 Total $ 5,897 $ 5,621 The inventory reserve balance at September 30, 2017 was $0.3 million. No reserve was required at December 31, 2016. During the three and nine months ended September 30, 2017, the Company recorded charges in the condensed consolidated statements of operations for excess and obsolete inventory of $0.3 million and $0.5 million, respectively. No charges were recorded for the three and nine months ended September 30, 2016 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(3) Goodwill and Intangible Assets Goodwill represents the excess of the purchase price over the fair value acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that fair value of the asset may be less than the carrying value of the asset. The Company determined a triggering event occurred in September 2017 based on Juniper’s announcement of a corporate reprioritization which aimed to re-focus its resources on the core business of Crinone® progesterone gel and JPS and to focus its research and development organization on its hormone replacement therapy initiative, its lead IVR program, and the Company would seek to partner its other IVR programs. In accordance with Accounting Standard Codification, or ASC 350, Goodwill and Other Intangibles Juniper concluded that the business represents two reporting units for goodwill impairment testing, which are product and service. Juniper’s goodwill is assigned to the Company’s service reporting unit. Juniper performed an impairment test as of the date of the triggering event and determined the Company’s goodwill is not impaired as of that date. Changes to goodwill during the nine months ended September 30, 2017 were as follows (in thousands): Total Balance—December 31, 2016 $ 8,342 Effects of foreign currency translation 714 Balance—September 30, 2017 $ 9,056 Intangible assets consist of the following at September 30, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (65 ) (206 ) (187 ) (458 ) Accumulated amortization (235 ) (792 ) (608 ) (1,635 ) Balance—September 30, 2017 $ — $ 372 $ 445 $ 817 Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance—December 31, 2016 $ — $ 455 $ 514 $ 969 Amortization expense related to developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations. Amortization expense for the three months ended September 30, 2017 and 2016 was $0.1 million. Amortization expense for the nine months ended September 30, 2017 and 2016 was $0.2 million and $0.3 million, respectively. Amortization expense on existing intangible assets as of September 30, 2017 is as follows (in thousands): Year ending December 31, Total Remainder of 2017 $ 78 2018 287 2019 260 2020 192 Total $ 817

Debt and other Contractual Obli

Debt and other Contractual Obligations	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt and other Contractual Obligations	(4) Debt and other Contractual Obligations In September 2013, Juniper assumed debt of $3.9 million in connection with its acquisition of Juniper Pharma Services (“JPS”). JPS had entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities (collectively referred to as the “original agreements”) with Lloyds TSB Bank (“Lloyds”) as administrative agent. In May 2017, JPS repaid one of the existing loan facilities upon which JPS subsequently entered into a new loan facility with the same administrative agent for the same outstanding balance. The refinancing was accounted for as a modification with no resulting gain or loss. The remaining original agreements and the new agreement are collectively referred to as the “loan facilities”. As of September 30, 2017, the Company owed $2.5 million on the loan facilities. The loan facilities are due for repayment over periods ranging from 7-15 years. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95%, and 2.55%, respectively. The interest rates at September 30, 2017 for these facilities were 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 2.99% per annum. The weighted average interest rate for the three loan facilities for the three months ended September 30, 2017 was 2.76%. The Loan Agreement is secured by the mortgaged property and an unlimited lien on other assets of JPS. The original agreements under the Loan Agreement contains financial covenants that limit the amount of indebtedness JPS may incur, requires JPS to maintain certain levels of net worth, and restricts JPS’s ability to materially alter the character of its business. The new loan facility contains the same financial covenants outlined above in addition to a covenant which requires that JPS maintain certain levels of earnings before interest, taxes, depreciation and amortization. As of September 30, 2017, the Company is in compliance with all of the covenants under the Loan Agreement. In September 2013, as part of the acquisition of JPS, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. JPS used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As part of the arrangement, JPS is required to create and maintain certain full-time equivalent personnel levels through October 1, 2017. As of September 30, 2017, the Company is in compliance with the covenants of the arrangement. The obligation ended on October 1, 2017. As of the date of this filing, the Company’s obligation under the grant arrangement is complete and the Company met all compliance requirements through October 1, 2017. The income from the Regional Growth Fund was on a decelerated basis through October 1, 2017. As of September 30, 2017, the Company had recorded all deferred revenue previously recognized under this arrangement. Other income associated with the Regional Growth Fund obligation for the three months ended September 30, 2017 and 2016 was $0.2 million and $0.2 million, respectively. Other income associated with the Regional Growth Fund obligation for the nine months ended September 30, 2017 and 2016 was $0.6 million and $0.5 million, respectively. Juniper leases its U.S. corporate office under an operating lease. Additionally, Juniper financed certain equipment under loan agreements with payments through March 2022. In October 2015, the Company entered into a lease agreement for its corporate office in Boston, Massachusetts. The initial term of the lease agreement is approximately 39 months and ends in 2019, which includes a three-month free rent period. In January and March 2017, the Company entered into loans of $0.9 million and $0.6 million, respectively, for equipment in its Nottingham, U.K. facility. The interest rate for the two loans was 2.09% at September 30, 2017. The transactions were considered failed sales-leaseback arrangements as the Company will obtain title to the equipment at the end of the term of the financing for little or no consideration. These failed sale-leaseback arrangements have been recorded as a component of long-term debt on the Company’s condensed consolidated balance sheets. The initial terms of the loans are 60 months. Commitments under Juniper’s debt and lease arrangements are as follows as of September 30, 2017 (in thousands): Operating Leases Debt Principal Payments Total Remainder of 2017 $ 109 $ 132 $ 241 2018 443 540 983 2019 74 563 637 2020 — 582 582 2021 — 602 602 Thereafter — 1,485 1,485 Total minimum debt and lease payments $ 626 $ 3,904 $ 4,530

Intravaginal Ring Technology Li

Intravaginal Ring Technology License	9 Months Ended
	Sep. 30, 2017
Licensing Activities [Abstract]
Intravaginal Ring Technology License	(5) Intravaginal Ring Technology License In March 2015, the Company obtained an exclusive worldwide license (“License Agreement”) to the intellectual property rights for a novel segmented intravaginal ring (“IVR”) technology. Due to its novel polymer and segmentation composition, the Company believes the IVR has the potential to deliver one or more drugs, including hormones and larger molecules such as peptides, at different dosages and release rates within a single segmented ring. Drugs such as progesterone and leuprolide have already been tested using the technology and demonstrated sustained release for up to three weeks. This technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology (“MIT”) and Dr. William Crowley from Massachusetts General Hospital (“MGH”) and Harvard Medical School. Drs. Langer and Crowley have each agreed to serve a three-year term as strategic advisors to the Company in exchange for an upfront one-time payment plus quarterly fees and equity compensation. Unless earlier terminated by the parties, the License Agreement will remain in effect until the later of (i) the date on which all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned and (ii) one year after the last sale for which a royalty is due under the License Agreement or 10 years after such expiration or abandonment date referred to in (i), whichever is earlier. Juniper has the right to terminate the License Agreement by giving 90 days advance written notice to MGH. MGH has the right to terminate the License Agreement based on the Company’s failure to make payments due under the License Agreement, subject to a 15 day cure period, or the Company’s failure to maintain the insurance required by the License Agreement. MGH may also terminate the License Agreement based on Juniper’s non-financial default under the License Agreement, subject to a 60 day cure period. Pursuant to the terms of the License Agreement, Juniper has agreed to reimburse MGH for all costs associated with the preparation, filing, prosecution and maintenance of the licensed patent rights, and has agreed to pay MGH a $50,000 annual license fee on each of the first five year anniversaries of the effective date of the License Agreement, and a $100,000 annual license fee beginning on the sixth anniversary of the effective date of the License Agreement and on each subsequent anniversary thereafter. The annual license fee is creditable against any royalties or sublicense income payable in each calendar year. Under the terms of the License Agreement, Juniper has agreed to use commercially reasonable efforts to develop and commercialize at least one product and/or process related to the IVR technology, which efforts will include the making of certain minimum annual expenditures in each of the first five years following the effective date of the License Agreement. Juniper has also agreed to pay MGH certain milestone payments totaling up to $1.2 million tied to the Company’s achievement of certain development and commercialization milestones, and certain annual royalty payments based on net sales of any such patented products or processes developed by Juniper.

Segments and Geographic Informa

Segments and Geographic Information	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segments and Geographic Information	(6) Segments and Geographic Information The Company and its subsidiaries currently operate in two segments: product and service. The product segment oversees the supply chain and manufacturing of Crinone, the Company’s sole commercialized product. The product segment included the royalty stream the Company received from Allergan for Crinone sales in the United States, which ceased with the November 2016 agreement with Allergan, as well as the development of new product candidates. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services for the Company’s customers, as well as the characterizing and developing of pharmaceutical product candidates for the Company’s internal programs and managing certain preclinical activities including manufacturing of the Company’s pipeline products. In September 2013, the Company acquired JPS, a U.K.-based provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry. The Company conducts its advanced formulation, analytical and consulting services through JPS. The Company has integrated its supply chain management for its sole commercialized product, Crinone, into those operations and have therefore sought to capture synergies by transferring all operational activities related to its historic business. The Company owns certain plant and equipment physically located at third party contractor facilities in the United Kingdom and Switzerland. The Company’s largest customer, Merck KGaA, utilizes a Switzerland-based subsidiary to acquire product from the Company, which it then sells throughout the world excluding the United States. Up until November 2016, the Company’s primary domestic customer, Allergan, Plc (“Allergan”), was responsible for the commercialization and sale of Crinone in the United States. In November 2016, the Company entered into an agreement with Allergan to monetize future royalty payments. Under the agreement, the Company received a one-time payment of $11.0 million representing all future royalty amounts payable. The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 United States $ 3,230 $ 2,851 $ 7,245 $ 7,066 Switzerland 8,505 7,081 26,021 20,772 United Kingdom 751 981 2,788 3,474 Other countries 500 643 2,135 2,331 Total $ 12,986 $ 11,556 $ 38,189 $ 33,643 Total assets: September 30, 2017 December 31, 2016 United States $ 22,780 $ 21,423 Switzerland 3,358 4,673 United Kingdom 35,529 31,288 Other countries 88 187 Total $ 61,755 $ 57,571 Long-lived assets: September 30, 2017 December 31, 2016 United States $ 500 $ 663 Switzerland 438 369 United Kingdom 15,083 13,468 Other countries 2 2 Total $ 16,023 $ 14,502 Long-lived assets include fixed assets, intangibles and other assets. No other individual country represented greater than 10% of total revenues, total assets, or long-lived assets for any period presented. For the three and nine months ended September 30, 2017, Merck KGaA accounted for 100% of the product segment revenue. For the three and nine months ended September 30, 2016, Merck KGaA accounted for 86% and 87% of the product segment revenue, respectively. For the three and nine months ended September 30, 2016, Allergan accounted for 14% and 13% of the product segment revenue, respectively. At September 30, 2017 and December 31, 2016, Merck KGaA made up 100% of the product segment accounts receivable. For the three and nine months ended September 30, 2017 the same customer accounted for 46% and 31% of the service segment total revenue, respectively. No customers accounted for 10% or more of the service segment total revenue for the three and nine months ended September 30, 2016. At September 30, 2017, one customer accounted for 41% of total service segment accounts receivable, respectively. At December 31, 2016, two customers accounted for 18% and 13% of total service segment net accounts receivable. The following summarizes other information by segment for the three months ended September 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 8,389 $ — $ 8,389 Service revenues — 4,597 4,597 Total revenues $ 8,389 $ 4,597 $ 12,986 Cost of product revenues $ 5,160 $ — $ 5,160 Cost of service revenues — 2,559 2,559 Total cost of revenues $ 5,160 $ 2,559 $ 7,719 Gross profit $ 3,229 $ 2,038 $ 5,267 Total operating expenses 6,802 Total non-operating expense 80 Loss before income taxes $ (1,455 ) The following summarizes other information by segment for the three months ended September 30, 2016 (in thousands): Product Service Total Revenues Product revenues $ 7,057 $ — $ 7,057 Service revenues — 3,337 3,337 Royalties 1,162 — 1,162 Total revenues $ 8,219 $ 3,337 $ 11,556 Cost of product revenues $ 3,683 $ — $ 3,683 Cost of service revenues — 2,022 2,022 Total cost of revenues $ 3,683 $ 2,022 $ 5,705 Gross profit $ 4,536 $ 1,315 $ 5,851 Total operating expenses 5,674 Total non-operating income 66 Income before income taxes $ 243 The following summarizes other information by segment for the nine months ended September 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 25,684 $ — $ 25,684 Service revenues — 12,505 12,505 Total revenues $ 25,684 $ 12,505 $ 38,189 Cost of product revenues $ 14,776 $ — $ 14,776 Cost of service revenues $ — $ 7,149 $ 7,149 Total cost of revenues 14,776 7,149 21,925 Gross profit $ 10,908 $ 5,356 $ 16,264 Total operating expenses 19,610 Total non-operating expense 74 Loss before income taxes $ (3,272 ) The following summarizes other information by segment for the nine months ended September 30, 2016 (in thousands): Product Service Total Revenues Product revenues $ 20,716 $ — $ 20,716 Service revenues — 9,964 9,964 Royalties 2,963 — 2,963 Total revenues $ 23,679 $ 9,964 $ 33,643 Cost of product revenues $ 11,892 $ — $ 11,892 Cost of service revenues — 6,630 6,630 Total cost of revenues $ 11,892 $ 6,630 $ 18,522 Gross profit $ 11,787 $ 3,334 $ 15,121 Total operating expenses 18,959 Total non-operating income 222 Loss before income taxes $ (3,616 )

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	(7) Property and Equipment Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) September 30, 2017 December 31, 2016 Machinery and equipment 3-10 $ 11,765 $ 8,628 Furniture and fixtures 3-5 1,083 1,190 Computer equipment and software 3-5 625 538 Buildings Up to 39 7,936 7,310 Land Indefinite 509 469 Construction in-process 1,150 1,567 23,068 19,702 Less: Accumulated depreciation (7,941 ) (6,336 ) Total $ 15,127 $ 13,366 Depreciation expense was $0.5 million and $0.4 million for the three-month periods ended September 30, 2017 and 2016, respectively. Depreciation expense was $1.4 million and $1.1 million for the nine month periods ended September 30, 2017 and 2016, respectively. The Company recorded $0 and $0.2 million in disposals during the three and nine months ended September 30, 2017. The Company recorded an impairment of $14,000 as a component of the Restructuring charge (See Note 15) recorded during the three months ended September 30, 2017, associated with the discontinuation of use on assets used in its new product research and development group. Machinery and equipment includes $1.5 million of equipment purchased under equipment loans.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Shareholders’ Equity	(8) Shareholders’ Equity Preferred Stock At December 31, 2016, 130 shares of Series B Preferred Stock (“Series B”) and 550 shares of Series C Preferred Stock (“Series C”) remained outstanding. During the quarter ending June 30, 2017, the Company issued a Notice of Conversion to the holders of the Series B and a Notice of Redemption to the Series C giving notice that on June 30, 2017 (the “Redemption and Conversion Date”) all outstanding shares of the respective Preferred Stock issuances would be converted, as in the case of the Series B, or redeemed, as in the case of the Series C. The Series B, by its terms, automatically convert into common stock upon the occurrence of certain events. On the Redemption and Conversion Date, each share of Series B converted into 2.78 shares of common stock resulting in an issuance of 361 common shares. The holders of the Series C had the right to require the Company to redeem their shares in cash plus all accrued and unpaid dividends thereon the date such redemption is demanded. On the Redemption and Conversion Date, the Company paid to the holders of the Series C approximately $0.1 million and as a result of the transaction recorded the excess of the carrying value of Series C Preferred Stock over redemption value of approximately $0.5 million to accumulated deficit for the nine months ended September 30, 2017. There were no remaining outstanding shares of either the Series B or the Series C following the Redemption and Conversion Date.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Common Share	(9) Net Loss Per Common Share The calculation of basic and diluted loss per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic net (loss) income per common share Net (loss) income $ (1,410 ) $ 248 $ (3,227 ) $ (3,663 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value — — 459 — Less: Preferred stock dividends — (7 ) (14 ) (21 ) Net (loss) income applicable to common stock $ (1,410 ) $ 241 $ (2,782 ) $ (3,684 ) Basic weighted average number of common shares outstanding 10,844 10,799 10,817 10,791 Basic net (loss) income per common share $ (0.13 ) $ 0.02 $ (0.26 ) $ (0.34 ) Diluted (loss) income per common share Net (loss) income applicable to common stock $ (1,410 ) $ 241 $ (2,782 ) $ (3,684 ) Less: Excess of carrying value of Series C Preferred Stock over redemption value — — — — Add: Preferred stock dividends — 7 — — Net (loss) income applicable to dilutive common stock $ (1,410 ) $ 248 $ (2,782 ) $ (3,684 ) Basic weighted average number of common shares outstanding 10,844 10,799 10,817 10,791 Effect of dilutive securities Dilutive stock awards — 178 — — Dilutive preferred share conversions — 83 — — — 261 — — Diluted weighted average number of common shares outstanding 10,844 11,060 10,817 10,791 Diluted net (loss) income per common share $ (0.13 ) $ 0.02 $ (0.26 ) $ (0.34 ) Basic net loss per common share is computed by dividing the net loss, less preferred dividends and adding the excess of carrying value of Series C Preferred Stock over redemption value recognized on the conversion of the Series C Preferred Stock, by the weighted-average number of shares of common stock outstanding during a period. The diluted loss per common share calculation gives effect to dilutive options, convertible preferred stock, and other potential dilutive common stock including restricted shares of common stock outstanding during the period. Diluted net loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options, performance-based restricted stock units, convertible preferred stock, and selected restricted shares of common stock excluded from the income per share calculation amounted to 2.2 million and 1.7 million in each of the three-month and nine-month periods ended September 30, 2017 and 2016, respectively, because the awards were anti-dilutive.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Accumulated Other Comprehensive Loss	(10) Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive loss during the nine months ended September 30, 2017 were as follows (in thousands): Translation Adjustment Balance—December 31, 2016 $ (5,028 ) Current period other comprehensive income (loss) 1,690 Balance—September 30, 2017 $ (3,338 )

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	(11) Stock-Based Compensation Stock-based compensation expense was $0.4 million and $0.3 million for the three months ended September 30, 2017 and 2016, respectively. Stock-based compensation expense for the nine months ended September 30, 2017 and 2016 was $1.2 million and $0.8 million, respectively. Stock-based compensation relates to options granted to employees, non-employee members of the Board of Directors and non-employees, time-based restricted stock units granted to employees and non-employee members of the Board of Directors and performance-based restricted stock units granted to employees. Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Cost of revenues $ 84 $ 94 $ 143 $ 152 Sales and marketing 12 17 35 48 Research and development (38 ) 23 (10 ) (14 ) General and administrative 313 195 1,048 618 Total $ 371 $ 329 $ 1,216 $ 804 There were no option exercises in the nine months ended September 30, 2017 and 2016. Juniper granted options to purchase 680,400 shares of common stock to employees and non-employee directors during the nine months ended September 30, 2017 and options to purchase 642,500 shares of common stock to employees during the nine months ended September 30, 2016. No stock options were granted to non-employee directors during the nine months ended September 30, 2016. Stock options granted to employees typically vest over a four-year term. Stock options granted to non-employee directors typically vest over a three-year term. Juniper granted 52,700 time-based restricted stock units to employees and 66,234 time-based restricted stock units to non-employee directors during the nine months ended September 30, 2017. Juniper granted 42,203 restricted stock units to non-employee directors during the nine months ended September 30, 2016 Juniper granted 186,000 performance-based restricted stock units to employees during the nine months ended September 30, 2017. No performance-based restricted stock units were granted during the nine months ended September 30, 2016. The performance-based restricted stock units vest based on the occurrence of certain operational and strategic events which were determined by the Company’s Board of Directors. The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock options and estimates the fair value of time-based restricted stock units and performance-based restricted stock units based on the closing price of the Company’s common stock on the date of grant. The Company’s assumptions do not include an estimated forfeiture rate. Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Juniper’s estimated expected stock price volatility is based on its own historical volatility. Juniper’s expected term of options granted during the nine months ended September 30, 2017 and 2016 was derived using the simplified method for employees. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The weighted-average grant date fair values of options granted to employees during the nine months ended September 30, 2017 and 2016 were $2.43 and $4.71, respectively, using the following assumptions: Nine Months Ended September 30, 2017 2016 Risk free interest rate 1.45% - 1.59% 0.85% - 1.14% Expected term 4.5 - 4.75 years 4.75 years Dividend yield - - Expected volatility 53.15% - 55.20% 78.08% - 79.29% The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options, which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense. The stock-based compensation expense recorded for non-employees is primarily reflected in the research and development line of the statement of operations and is remeasured on a quarterly basis from the date of grant. During the nine months ended September 30, 2017, the Company recorded a reduction of stock-based compensation expense of $0.1 million for non-employee options as a result of changes in the fair value of the options during the period. During the nine months ended September 30, 2016, the Company recorded a reduction of stock-based compensation expense of $0.2 million for non-employee options. No tax benefit has been recognized due to the net tax losses during the periods presented. There were no options granted to non-employees during the nine months ended September 30, 2017 and 2016. The weighted-average grant date fair value of both the time-based restricted stock units and performance-based restricted stock units was $4.97 per share during the nine months ended September 30, 2017. The Company recognizes stock-based compensation expense for time-based restricted stock units over the vesting period. For performance-based restricted stock units, the Company considers the performance criteria at each balance sheet date and recognizes stock-based compensation expense for those criteria considered probable. The criteria associated with these performance-based stock units were not determined to be probable at September 30, 2017 and as such, no expense was recorded. As of September 30, 2017, the total unrecognized compensation cost related to outstanding stock options, time-based restricted stock units and performance-based restricted stock units expected to vest was $4.4 million, which the Company expects to recognize over a weighted-average period of 3.55 years. During the three months ended September 30, 2017, in conjunction with the corporate reprioritization (see Note 15) announced in September 2017, the Company modified options held by an executive to extend the exercise period allowed and recorded incremental stock-based compensation of approximately $17,000 as a component of Restructuring expense. The Company recognized the forfeiture on unvested awards upon the executive’s departure and has recognized a reduction in stock-based compensation of approximately $68,000 during the period ended September 30, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(12) Fair Value of Financial Instruments U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at September 30, 2017 and December 31, 2016. The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement. During the three and nine months ended September 30, 2017, the Company did not have transfers of financial assets between Level 1 and 2.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes During the three and nine months ended September 30, 2017, Juniper recorded an income tax benefit of $45,000, representing an effective tax rate of 3.1% and 1.4%, respectively. This benefit reflecting an adjustment to the Company’s foreign income inclusion for U.S. tax purposes, which reduced its alternative minimum tax recorded in 2016. No income tax expense has been recorded due to expected losses forecasted for the year. During the three months ended September 30, 2016, Juniper recorded income tax benefit of $5,000, representing an effective tax rate of (2.1)%. During the nine months ended September 30, 2016, Juniper recorded income tax expense of $47,000, representing an effective tax rate of (1.3)%. The income tax provision for the three and nine months ended September 30, 2016, is primarily attributable to alternative minimum taxes. Juniper files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Juniper is no longer subject to U.S. federal income tax examinations by tax authorities for years prior to 2012. Additionally, with few exceptions, Juniper is no longer subject to U.S. state tax examinations for years prior to 2012.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2017
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	(14) Recent Accounting Pronouncements Adopted In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory To be adopted In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment On August 26, 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net) , Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers

Restructuring Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2017
Restructuring And Related Activities [Abstract]
Restructuring Charges	(15) Restructuring Charges In September 2017, the Company announced a corporate reprioritization which aimed to re-focus its resources on the core businesses of Crinone progesterone gel and JPS and reduce expenditures on research and development activities associated with the Company’s intravaginal ring (IVR) program with the goal of potentially identifying a partner for one or more of its IVR product candidates. As a result, during the three and nine months ended September 30, 2017, the Company incurred approximately $0.8 million in restructuring charges. The Company accounted for these actions in accordance with ASC 420, Exit or Disposal Cost Obligations No significant additional charges are anticipated relating to this restructuring plan. The Company has recorded a liability totaling approximately $0.7 million for ongoing payments due associated with severance and employee-related costs and future contractual obligations. Severance payments totaling approximately $23,000 were paid during the three months ended September 30, 2017. The Company expects to pay approximately $0.3 million during the remainder of 2017 and approximately $0.4 million in 2018 and beyond.

Interim Condensed Consolidate22

Interim Condensed Consolidated Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, restructuring charges and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Goodwill and Intangible Assets	Goodwill represents the excess of the purchase price over the fair value acquired and liabilities assumed in a business combination. The Company does not amortize its goodwill, but instead tests for impairment annually in the fourth quarter and more frequently whenever events or changes in circumstances indicate that fair value of the asset may be less than the carrying value of the asset. The Company determined a triggering event occurred in September 2017 based on Juniper’s announcement of a corporate reprioritization which aimed to re-focus its resources on the core business of Crinone® progesterone gel and JPS and to focus its research and development organization on its hormone replacement therapy initiative, its lead IVR program, and the Company would seek to partner its other IVR programs. In accordance with Accounting Standard Codification, or ASC 350, Goodwill and Other Intangibles Juniper concluded that the business represents two reporting units for goodwill impairment testing, which are product and service. Juniper’s goodwill is assigned to the Company’s service reporting unit. Juniper performed an impairment test as of the date of the triggering event and determined the Company’s goodwill is not impaired as of that date.
Recent Accounting Pronouncements	Adopted In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory To be adopted In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment On August 26, 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued ASU No. 2016-02, Leases In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Recognition and Measurement of Financial Assets and Financial Liabilities In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers Revenue Recognition Revenue Recognition-Construction-Type and Production-Type Contracts Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net) , Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): September 30, 2017 December 31, 2016 Raw materials $ 2,020 $ 856 Work in process 3,099 3,806 Finished goods 778 959 Total $ 5,897 $ 5,621

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the nine months ended September 30, 2017 were as follows (in thousands): Total Balance—December 31, 2016 $ 8,342 Effects of foreign currency translation 714 Balance—September 30, 2017 $ 9,056
Changes to Intangible Assets	Intangible assets consist of the following at September 30, 2017 and December 31, 2016 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (65 ) (206 ) (187 ) (458 ) Accumulated amortization (235 ) (792 ) (608 ) (1,635 ) Balance—September 30, 2017 $ — $ 372 $ 445 $ 817 Trademark Developed Technology Customer Relationships Total Gross carrying amount $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (53 ) (298 ) (270 ) (621 ) Accumulated amortization (247 ) (617 ) (456 ) (1,320 ) Balance—December 31, 2016 $ — $ 455 $ 514 $ 969
Amortization Expense on Existing Intangible Assets	Amortization expense on existing intangible assets as of September 30, 2017 is as follows (in thousands): Year ending December 31, Total Remainder of 2017 $ 78 2018 287 2019 260 2020 192 Total $ 817

Debt and other Contractual Ob25

Debt and other Contractual Obligations (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Commitments Under Juniper's Debt and Lease Arrangements	Commitments under Juniper’s debt and lease arrangements are as follows as of September 30, 2017 (in thousands): Operating Leases Debt Principal Payments Total Remainder of 2017 $ 109 $ 132 $ 241 2018 443 540 983 2019 74 563 637 2020 — 582 582 2021 — 602 602 Thereafter — 1,485 1,485 Total minimum debt and lease payments $ 626 $ 3,904 $ 4,530

Segments and Geographic Infor26

Segments and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Selected Information by Geographic Area	The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 United States $ 3,230 $ 2,851 $ 7,245 $ 7,066 Switzerland 8,505 7,081 26,021 20,772 United Kingdom 751 981 2,788 3,474 Other countries 500 643 2,135 2,331 Total $ 12,986 $ 11,556 $ 38,189 $ 33,643 Total assets: September 30, 2017 December 31, 2016 United States $ 22,780 $ 21,423 Switzerland 3,358 4,673 United Kingdom 35,529 31,288 Other countries 88 187 Total $ 61,755 $ 57,571 Long-lived assets: September 30, 2017 December 31, 2016 United States $ 500 $ 663 Switzerland 438 369 United Kingdom 15,083 13,468 Other countries 2 2 Total $ 16,023 $ 14,502
Schedule of Other Information by Segment	The following summarizes other information by segment for the three months ended September 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 8,389 $ — $ 8,389 Service revenues — 4,597 4,597 Total revenues $ 8,389 $ 4,597 $ 12,986 Cost of product revenues $ 5,160 $ — $ 5,160 Cost of service revenues — 2,559 2,559 Total cost of revenues $ 5,160 $ 2,559 $ 7,719 Gross profit $ 3,229 $ 2,038 $ 5,267 Total operating expenses 6,802 Total non-operating expense 80 Loss before income taxes $ (1,455 ) The following summarizes other information by segment for the three months ended September 30, 2016 (in thousands): Product Service Total Revenues Product revenues $ 7,057 $ — $ 7,057 Service revenues — 3,337 3,337 Royalties 1,162 — 1,162 Total revenues $ 8,219 $ 3,337 $ 11,556 Cost of product revenues $ 3,683 $ — $ 3,683 Cost of service revenues — 2,022 2,022 Total cost of revenues $ 3,683 $ 2,022 $ 5,705 Gross profit $ 4,536 $ 1,315 $ 5,851 Total operating expenses 5,674 Total non-operating income 66 Income before income taxes $ 243 The following summarizes other information by segment for the nine months ended September 30, 2017 (in thousands): Product Service Total Revenues Product revenues $ 25,684 $ — $ 25,684 Service revenues — 12,505 12,505 Total revenues $ 25,684 $ 12,505 $ 38,189 Cost of product revenues $ 14,776 $ — $ 14,776 Cost of service revenues $ — $ 7,149 $ 7,149 Total cost of revenues 14,776 7,149 21,925 Gross profit $ 10,908 $ 5,356 $ 16,264 Total operating expenses 19,610 Total non-operating expense 74 Loss before income taxes $ (3,272 ) The following summarizes other information by segment for the nine months ended September 30, 2016 (in thousands): Product Service Total Revenues Product revenues $ 20,716 $ — $ 20,716 Service revenues — 9,964 9,964 Royalties 2,963 — 2,963 Total revenues $ 23,679 $ 9,964 $ 33,643 Cost of product revenues $ 11,892 $ — $ 11,892 Cost of service revenues — 6,630 6,630 Total cost of revenues $ 11,892 $ 6,630 $ 18,522 Gross profit $ 11,787 $ 3,334 $ 15,121 Total operating expenses 18,959 Total non-operating income 222 Loss before income taxes $ (3,616 )

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): Estimated Useful Life (Years) September 30, 2017 December 31, 2016 Machinery and equipment 3-10 $ 11,765 $ 8,628 Furniture and fixtures 3-5 1,083 1,190 Computer equipment and software 3-5 625 538 Buildings Up to 39 7,936 7,310 Land Indefinite 509 469 Construction in-process 1,150 1,567 23,068 19,702 Less: Accumulated depreciation (7,941 ) (6,336 ) Total $ 15,127 $ 13,366

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Loss Per Common Share and Common Share Equivalents	The calculation of basic and diluted loss per common share and common share equivalents is as follows (in thousands except for per share data): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic net (loss) income per common share Net (loss) income $ (1,410 ) $ 248 $ (3,227 ) $ (3,663 ) Add: Excess of carrying value of Series C Preferred Stock over redemption value — — 459 — Less: Preferred stock dividends — (7 ) (14 ) (21 ) Net (loss) income applicable to common stock $ (1,410 ) $ 241 $ (2,782 ) $ (3,684 ) Basic weighted average number of common shares outstanding 10,844 10,799 10,817 10,791 Basic net (loss) income per common share $ (0.13 ) $ 0.02 $ (0.26 ) $ (0.34 ) Diluted (loss) income per common share Net (loss) income applicable to common stock $ (1,410 ) $ 241 $ (2,782 ) $ (3,684 ) Less: Excess of carrying value of Series C Preferred Stock over redemption value — — — — Add: Preferred stock dividends — 7 — — Net (loss) income applicable to dilutive common stock $ (1,410 ) $ 248 $ (2,782 ) $ (3,684 ) Basic weighted average number of common shares outstanding 10,844 10,799 10,817 10,791 Effect of dilutive securities Dilutive stock awards — 178 — — Dilutive preferred share conversions — 83 — — — 261 — — Diluted weighted average number of common shares outstanding 10,844 11,060 10,817 10,791 Diluted net (loss) income per common share $ (0.13 ) $ 0.02 $ (0.26 ) $ (0.34 )

Accumulated Other Comprehensi29

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Changes to accumulated other comprehensive loss during the nine months ended September 30, 2017 were as follows (in thousands): Translation Adjustment Balance—December 31, 2016 $ (5,028 ) Current period other comprehensive income (loss) 1,690 Balance—September 30, 2017 $ (3,338 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Schedule of Stock-Based Compensation Expense Allocation	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective awards as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Cost of revenues $ 84 $ 94 $ 143 $ 152 Sales and marketing 12 17 35 48 Research and development (38 ) 23 (10 ) (14 ) General and administrative 313 195 1,048 618 Total $ 371 $ 329 $ 1,216 $ 804
Employees [Member]
Assumptions Used to Value Options Granted	The weighted-average grant date fair values of options granted to employees during the nine months ended September 30, 2017 and 2016 were $2.43 and $4.71, respectively, using the following assumptions Nine Months Ended September 30, 2017 2016 Risk free interest rate 1.45% - 1.59% 0.85% - 1.14% Expected term 4.5 - 4.75 years 4.75 years Dividend yield - - Expected volatility 53.15% - 55.20% 78.08% - 79.29%

Interim Condensed Consolidate31

Interim Condensed Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cash and cash equivalents	$ 22,106	$ 20,994	$ 14,971	$ 13,901

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Net Items Net Of Reserve Alternative [Abstract]
Raw materials	$ 2,020	$ 856
Work in process	3,099	3,806
Finished goods	778	959
Total	$ 5,897	$ 5,621

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Inventory Net Items Net Of Reserve Alternative [Abstract]
Inventory reserve balance	$ 300,000		$ 300,000		$ 0
Charges for excess and obsolete inventory	$ 300,000	$ 0	$ 500,000	$ 0

Goodwill and Intangible Asset34

Goodwill and Intangible Assets - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)ReportingUnit	Sep. 30, 2016USD ($)
Intangible Liability Disclosure [Abstract]
Number of reporting unit | ReportingUnit			2
Goodwill impaired	$ 0		$ 0
Amortization expense	$ 100,000	$ 100,000	$ 200,000	$ 300,000

Goodwill and Intangible Asset35

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning balance	$ 8,342
Effects of foreign currency translation	714
Ending balance	$ 9,056

Goodwill and Intangible Asset36

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,910	$ 2,910
Foreign currency translation adjustment	(458)	(621)
Accumulated amortization	(1,635)	(1,320)
Balance	817	969
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	300	300
Foreign currency translation adjustment	(65)	(53)
Accumulated amortization	(235)	(247)
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,370	1,370
Foreign currency translation adjustment	(206)	(298)
Accumulated amortization	(792)	(617)
Balance	372	455
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,240	1,240
Foreign currency translation adjustment	(187)	(270)
Accumulated amortization	(608)	(456)
Balance	$ 445	$ 514

Goodwill and Intangible Asset37

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
Remainder of 2017	$ 78
2,018	287
2,019	260
2,020	192
Total	$ 817	$ 969

Debt and Other Contractual Ob38

Debt and Other Contractual Obligations - Additional Information (Detail)	1 Months Ended				3 Months Ended		9 Months Ended
	May 31, 2017Facility	Mar. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Sep. 30, 2013USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)FacilityLoan	Sep. 30, 2016USD ($)
Debt Instrument [Line Items]
Amount owe under loan facility					$ 3,904,000		$ 3,904,000
Lease agreement term							39 months
Lease agreement rent free period							3 months
Capital lease term							60 months
Lease agreement, expiration year							2,019
Proceeds from equipment loans							$ 1,501,000
Loan for Equipment [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Number of loans | Loan							2
Loan for Equipment [Member] | Loan One [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rates at the end of period					2.09%		2.09%
Proceeds from equipment loans			$ 900,000
Loan for Equipment [Member] | Loan Two [Member] | Nottingham, UK Facility [Member]
Debt Instrument [Line Items]
Interest rates at the end of period					2.09%		2.09%
Proceeds from equipment loans		$ 600,000
Juniper Pharma Services [Member]
Debt Instrument [Line Items]
Debt assumed				$ 3,900,000
Number of loan facilities | Facility							3
Number of loan facilities repaid | Facility	1
Gain loss on refinancing of debt							$ 0
Amount owe under loan facility					$ 2,500,000		$ 2,500,000
Weighted average interest rate for the period					2.76%		2.76%
Juniper Pharma Services [Member] | Regional Growth Fund [Member]
Debt Instrument [Line Items]
Debt assumed				$ 2,500,000
Other income					$ 200,000	$ 200,000	$ 600,000	$ 500,000
Obligation under a grant arrangement, maturity date							Oct. 1, 2017
Juniper Pharma Services [Member] | Minimum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period							7 years
Juniper Pharma Services [Member] | Maximum [Member]
Debt Instrument [Line Items]
Loan facilities repayment period							15 years
Juniper Pharma Services [Member] | Loan Facility One [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate							1.95%
Loan facility interest rate description							base rate plus 1.95%
Interest rates at the end of period					2.45%		2.45%
Juniper Pharma Services [Member] | Loan Facility Two [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate							2.55%
Loan facility interest rate description							base rate plus 2.55%
Interest rates at the end of period					3.05%		3.05%
Juniper Pharma Services [Member] | Loan Facility Three [Member]
Debt Instrument [Line Items]
Loan facilities bear interest rate					2.99%		2.99%

Debt and Other Contractual Ob39

Debt and Other Contractual Obligations - Schedule of Commitments Under Juniper's Debt and Lease Arrangements (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Debt Disclosure [Abstract]
Operating Leases, Remainder of 2017	$ 109
Operating Leases, 2018	443
Operating Leases, 2019	74
Operating Leases, Total minimum lease payments	626
Debt Principal Payments, Remainder of 2017	132
Debt Principal Payments, 2018	540
Debt Principal Payments, 2019	563
Debt Principal Payments, 2020	582
Debt Principal Payments, 2021	602
Debt Principal Payments, Thereafter	1,485
Total Debt Principal Payments, minimum	3,904
Total Debt and Lease payments, Remainder of 2017	241
Total Debt and Lease payments, 2018	983
Total Debt and Lease payments, 2019	637
Total Debt and Lease payments, 2020	582
Total Debt and Lease payments, 2021	602
Total Debt and Lease payments, Thereafter	1,485
Total minimum debt and lease payments	$ 4,530

Intravaginal Ring Technology 40

Intravaginal Ring Technology License - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017USD ($)
License Agreements [Line Items]
License agreement notice period	90 days
License fee payment	$ 50,000
License fee payment beginning on the sixth anniversary	100,000
Milestone payment	$ 1,200,000
Financial Default [Member]
License Agreements [Line Items]
Cure period	15 days
Non Financial Default [Member]
License Agreements [Line Items]
Cure period	60 days

Segments and Geographic Infor41

Segments and Geographic Information - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2016USD ($)	Sep. 30, 2017	Sep. 30, 2016USD ($)Customer	Sep. 30, 2017SegmentCustomer	Sep. 30, 2016USD ($)Customer	Dec. 31, 2016Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | Segment				2
One time payment, royalty revenues | $			$ 1,162		$ 2,963
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Customers accounted for 10% or more of total revenues | Customer			0		0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		46.00%		31.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customers | Customer				1		2
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage				41.00%		18.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Service [Member] | Customer Two [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage						13.00%
Allergan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
One time payment, royalty revenues | $	$ 11,000
Allergan [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			14.00%		13.00%
Merck KGaA [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		100.00%	86.00%	100.00%	87.00%
Merck KGaA [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] | Product Segment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage				100.00%		100.00%

Segments and Geographic Infor42

Segments and Geographic Information - Selected Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 12,986	$ 11,556	$ 38,189	$ 33,643
Total assets	61,755		61,755		$ 57,571
Total Long-lived assets	16,023		16,023		14,502
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	3,230	2,851	7,245	7,066
Total assets	22,780		22,780		21,423
Total Long-lived assets	500		500		663
Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	8,505	7,081	26,021	20,772
Total assets	3,358		3,358		4,673
Total Long-lived assets	438		438		369
Nottingham, UK Facility [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	751	981	2,788	3,474
Total assets	35,529		35,529		31,288
Total Long-lived assets	15,083		15,083		13,468
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	500	$ 643	2,135	$ 2,331
Total assets	88		88		187
Total Long-lived assets	$ 2		$ 2		$ 2

Segments and Geographic Infor43

Segments and Geographic Information - Schedule of Other Information by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues
Product revenues	$ 8,389	$ 7,057	$ 25,684	$ 20,716
Service revenues	4,597	3,337	12,505	9,964
Royalties		1,162		2,963
Total revenues	12,986	11,556	38,189	33,643
Cost of product revenues	5,160	3,683	14,776	11,892
Cost of service revenues	2,559	2,022	7,149	6,630
Total cost of revenues	7,719	5,705	21,925	18,522
Gross profit	5,267	5,851	16,264	15,121
Total operating expenses	6,802	5,674	19,610	18,959
Total non-operating income (expense)	80	66	74	222
(Loss) income before income taxes	(1,455)	243	(3,272)	(3,616)
Product [Member]
Revenues
Product revenues	8,389	7,057	25,684	20,716
Royalties		1,162		2,963
Total revenues	8,389	8,219	25,684	23,679
Cost of product revenues	5,160	3,683	14,776	11,892
Total cost of revenues	5,160	3,683	14,776	11,892
Gross profit	3,229	4,536	10,908	11,787
Service [Member]
Revenues
Service revenues	4,597	3,337	12,505	9,964
Total revenues	4,597	3,337	12,505	9,964
Cost of service revenues	2,559	2,022	7,149	6,630
Total cost of revenues	2,559	2,022	7,149	6,630
Gross profit	$ 2,038	$ 1,315	$ 5,356	$ 3,334

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 23,068	$ 19,702
Less: Accumulated depreciation	(7,941)	(6,336)
Total	15,127	13,366
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 11,765	8,628
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,083	1,190
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 625	538
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 7,936	7,310
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 509	469
Property, plant and equipment useful life (in years)	Indefinite
Construction in-Process [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,150	$ 1,567

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 500,000	$ 400,000	$ 1,400,000	$ 1,100,000
Disposal of property and equipment	0		200,000
Equipment purchased under equipment loans			1,500,000
Restructuring charges	756,000		756,000
Fixed Asset Impairments [Member]
Property, Plant and Equipment [Line Items]
Restructuring charges	$ 14,000		$ 14,000

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) $ in Thousands	6 Months Ended	9 Months Ended
	Jun. 30, 2017USD ($)shares	Sep. 30, 2017USD ($)shares	Dec. 31, 2016shares
Class of Stock [Line Items]
Preferred stock, redemption date		Jun. 30, 2017
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding	0	0	130
Each share of preferred stock converted into common stock	2.78
Preferred shares converted into common stock, shares	361
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding	0	0	550
Payment for redemption of preferred stock | $	$ 100
Amount recorded in excess of carrying value over redemption value | $		$ 459

Net Loss Per Common Share - Cal

Net Loss Per Common Share - Calculation of Basic and Diluted Loss Per Common Share and Common Share Equivalents (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Basic net (loss) income per common share
Net (loss) income	$ (1,410)	$ 248	$ (3,227)	$ (3,663)
Less: Preferred stock dividends		(7)	(14)	(21)
Net (loss) income applicable to common stock	$ (1,410)	$ 241	$ (2,782)	$ (3,684)
Basic weighted average number of common shares outstanding	10,844	10,799	10,817	10,791
Basic net (loss) income per common share	$ (0.13)	$ 0.02	$ (0.26)	$ (0.34)
Diluted (loss) income per common share
Net (loss) income applicable to common stock	$ (1,410)	$ 241	$ (2,782)	$ (3,684)
Add: Preferred stock dividends		7
Net (loss) income applicable to dilutive common stock	$ (1,410)	$ 248	$ (2,782)	$ (3,684)
Basic weighted average number of common shares outstanding	10,844	10,799	10,817	10,791
Effect of dilutive securities
Dilutive stock awards		178
Dilutive preferred share conversions		83
Weighted average number of diluted shares outstanding adjustment		261
Diluted weighted average number of common shares outstanding	10,844	11,060	10,817	10,791
Diluted net (loss) income per common share	$ (0.13)	$ 0.02	$ (0.26)	$ (0.34)
Series C Preferred Stock [Member]
Basic net (loss) income per common share
Excess of carrying value of Series C Preferred Stock over redemption value			$ 459
Diluted (loss) income per common share
Excess of carrying value of Series C Preferred Stock over redemption value			$ 459

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	2.2	1.7	2.2	1.7

Accumulated Other Comprehensi49

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2016			$ 39,770
Current period other comprehensive income (loss)	$ 639	$ (658)	1,690	$ (2,863)
Balance—September 30, 2017	39,913		39,913
Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance—December 31, 2016			(5,028)
Current period other comprehensive income (loss)			1,690
Balance—September 30, 2017	$ (3,338)		$ (3,338)

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 400,000	$ 300,000	$ 1,200,000	$ 800,000
Stock option exercised			0	0
Tax benefit recognized			$ 0	$ 0
Stock-based compensation expense	371,000	$ 329,000	1,216,000	$ 804,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized	4,400,000		$ 4,400,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition			3 years 6 months 19 days
Reduction in share-based compensation expense in conjunction with corporate reprioritization			$ 68,000
Restructuring Charge [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock-based compensation	$ 17,000
Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair values of options granted			$ 4.97
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair values of options granted			$ 4.97
Stock-based compensation expense			$ 0
Employees and Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted			680,400
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted				642,500
Share-based compensation arrangement by share-based payment award, award vesting period			4 years
Weighted-average grant date fair values of options granted			$ 2.43	$ 4.71
Employees [Member] | Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted			52,700
Employees [Member] | Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted			186,000	0
Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted				0
Share-based compensation arrangement by share-based payment award, award vesting period			3 years
Non-Employee Directors [Member] | Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted			66,234
Non-Employee Directors [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-options stock granted				42,203
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted			0	0
Reduction of stock-based compensation expense			$ 100,000	$ 200,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 371	$ 329	$ 1,216	$ 804
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	84	94	143	152
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	12	17	35	48
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	(38)	23	(10)	(14)
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 313	$ 195	$ 1,048	$ 618

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Value Options Granted (Detail) - Employees [Member]	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		4 years 9 months
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.45%	0.85%
Expected term	4 years 6 months
Expected volatility	53.15%	78.08%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.59%	1.14%
Expected term	4 years 9 months
Expected volatility	55.20%	79.29%

Fair Value of Financial Instr53

Fair Value of Financial Instruments - Additional Information (Detail)	Sep. 30, 2017USD ($)
Fair Value Disclosures [Abstract]
Financial assets level 1 to level 2 transfers amount	$ 0
Financial assets level 2 to level 1 transfers amount	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (45,000)	$ (5,000)	$ (45,000)	$ 47,000
Effective tax rate	3.10%	(2.10%)	1.40%	(1.30%)
Income tax expense (benefit) expected losses forecasted			$ 0

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 756,000	$ 756,000
Additional restructuring charges		0
One-time Severance and Other Employee-related Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges		400,000
Future Obligations Due under Manufacturing and Development Contracts [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges		300,000
Stock-based Compensation Expense [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges		17,000
Fixed Asset Impairments [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges	14,000	14,000
Severance and Employee-related Costs and Future Contractual Obligations [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve	700,000	700,000
Restructuring payments expected to be paid in remainder of 2017	300,000	300,000
Restructuring payments expected to be paid in 2018 or beyond	400,000	$ 400,000
Severance [Member]
Restructuring Cost And Reserve [Line Items]
Payments for restructuring	$ 23,000